v3.25.2
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Patient revenue, net $ 72,050
Cost of revenues 305,248
Gross profit (loss) (233,198)
Operating expenses:    
General and administrative 5,390,069 2,941,624
Loss on disposition or impairment 3,433,884
Total operating expenses 5,390,069 6,375,508
Operating loss (5,623,267) (6,375,508)
Other income (expense):    
Interest income 3,470 27,156
Other income (expense) (2,040)
Interest expense (677,981) (124,966)
Total other income (expenses) (674,511) (99,850)
Net loss before income taxes (6,297,778) (6,475,358)
Income taxes
Net loss from continuing operations (6,297,778) (6,475,358)
Loss from operations of discontinued component (2,648,008) (1,707,342)
Loss on disposal of discontinued operations (100,041) (1,235,885)
Net loss from discontinued operations (2,748,049) (2,943,227)
Net loss (9,045,827) (9,418,585)
Preferred dividends (3,132,650) (130,000)
Net loss available to common stockholders $ (12,178,477) $ (9,548,585)
Net loss per share from continuing operations basic $ (6.01) $ (5.82)
Net loss per share from continuing operations diluted (6.01) (5.82)
Loss per share from discontinued operations - Basic (1.75) (2.65)
Loss per share from discontinued operations - diluted (1.75) (2.65)
Net loss per share basic (7.76) (8.47)
Net loss per share diluted $ (7.76) $ (8.47)
Weighted average common shares outstanding    
Weighted average common shares outstanding, basic 1,569,627 1,111,844
Weighted average common shares outstanding, diluted 1,569,627 1,111,844